Across Protocol vs Enzyme — how do they compare? Across Protocol trades at Rp739.48 (market cap Rp505,3M, Rp188,8M 24h volume), while Enzyme trades at Rp30,212 (market cap Rp134,13M, Rp104,56M 24h volume). The key difference: Across Protocol is far larger — about 3.8× Enzyme's market cap, and Across Protocol 's supply is capped (716,5M / 1B ACX (72%)) while Enzyme's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold Across Protocol for 57 Days and Enzyme for 29 Days on average.
| ACX | MLN | |
|---|---|---|
Market Cap | Rp505,3M | Rp134,13M |
Volume (24h) | Rp188,8M | Rp104,56M |
Circulating Supply | 716,5M / 1B ACX (72%) | 3,3M MLN |
Typical Hold Time | 57 Days | 29 Days |
Signals from Pluang's Aura AI — not financial advice
Across Protocol (ACX) is trading at Rp728.43 with a market cap of Rp505.3M, showing bearish technical signals with 15 sell signals versus 3 buys. The token is near its pivot point of Rp714, with key support at Rp665 and resistance at Rp751. With 72% of max supply in circulation and average hold time of 57 days, the token shows moderate distribution. No major protocol updates or ecosystem developments have been reported recently.
Overall outlook remains cautious with bearish technical dominance. Key opportunity lies in oversold RSI conditions suggesting potential bounce, while major risks include low liquidity and concentrated sell pressure. Investors should monitor support levels closely and watch for any protocol developments that could shift momentum.
Enzyme (MLN) shows limited market activity with a modest market cap of Rp134,13M and circulating supply of 3,3jt tokens. The asset demonstrates relatively low volatility with an average hold time of 29 days, suggesting stable holder behavior. Trading volumes appear subdued across exchanges, indicating limited speculative interest. No significant protocol upgrades or ecosystem developments have been reported recently, though the project continues to operate its decentralized asset management platform.
Overall outlook remains cautious due to limited liquidity and trading activity. Key opportunities include potential ecosystem growth in decentralized finance asset management, while major risks include low market depth, regulatory uncertainty for DeFi protocols, and competition from larger DeFi platforms. The token's utility within its native protocol remains its primary value driver.
Across (ACX) is a cross-chain token bridge secured by UMA's optimistic oracle. Designed for capital efficiency, ACX features a single liquidity pool, competitive relayer options, and a no-slippage fee model. Because its oracle verifies transfers optimistically, ACX is able to process cross-chain transfers quickly.
Read more on ACX →Enzyme is an easy-to-use on-chain asset management system that enables access to digital assets and DeFi from one simple, unified app. It provides a front-to-back execution and order management system, which provides fully automated reporting, risk management, administration, governance and operations.
Read more on MLN →